Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

Eurofins Scientific reports Q3 revenue growth, but warns of weaker organic growth in 2026

Eurofins Scientific increased group revenue in the third quarter by 6.1% to €1.91 billion and reported organic growth of 3.5%. Revenue in Europe rose 3.7% to €985 million, and in North America 7.9% to €712 million. For 2026 the company expects organic growth below its mid-single-digit target range, but aims to return to the targeted growth in 2027 and confirms an adjusted EBITDA margin of over 22.5%. The stock fell intraday after the more cautious outlook, but later reversed and again reached a 52-week high. » Mere på deraktionaer.de
Eurofins Scientific: €10,000 investment ten years ago would have grown to €18,888.59

Ten years ago the closing price of Eurofins Scientific shares was €37.43, meaning a €10,000 investment would have bought about 267.165 shares. At the closing price on 11 September 2026 of €70.70, that investment would be worth €18,888.59, an increase of 88.89 percent. Eurofins Scientific most recently reached a market capitalization of €12.27 billion; stock splits and dividends were not taken into account in the calculation. » Mere på finanzen.net
Eurofins Scientific reports weak organic growth in first half

Eurofins Scientific recorded organic growth of 2.7% in the first half, below market expectations. Its biopharma business and CDMO activities showed weakness, while product testing remained stable. Revenue of €3.701 billion matched consensus; adjusted EBITDA of €877 million and a margin of 23.7% beat expectations. Adjusted earnings per share rose 25% to €1.64 and free cash flow improved significantly; the company confirms its full-year guidance with mid-single-digit organic growth and margin improvement. » Mere på de.investing.com
Eurofins Scientific misses Q1 revenue forecast, shares fall 11%

Eurofins Scientific reported Q1 2026 revenue of USD 1.79 billion, missing the USD 1.81 billion forecast, weighed down by extreme weather in North America and northern Europe and by currency headwinds. The stock fell about 11.1% after the announcement and approached its 52-week low. Management remains confident it will achieve mid-single-digit organic growth and the planned margin expansion for the year through operational efficiency measures. » Mere på de.investing.com
Eurofins: earnings per share up 24%, organic growth accelerates

Eurofins reported for fiscal 2025 an increase in adjusted earnings per share of 24% to €2.31, with revenue up 5% to €7,296m and organic growth of 4.1% (3.9% H1 vs. 4.4% H2). Adjusted EBITDA rose 6% to €1,641m with a margin of 22.5%; free cash flow improved 9% to €876m. The company highlighted operational efficiency, working-capital improvements and continued M&A activity; net debt stands at 2.2x. For 2026 Eurofins expects mid-single-digit organic growth, and it confirmed its 2027 targets of 6.5% annual organic growth and a 24% adjusted EBITDA margin; the stock fell about 5% on the day of the release. » Mere på de.investing.com

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2026 har Eurofins Scientific allerede udloddet 0,61 € i udbytte. Den seneste udlodning fandt sted i april.

Virksomhedstal

I det seneste kvartal havde Eurofins Scientific en omsætning på 3,7 mia. € og et nettoresultat på 302 mio. €

(EUR)	juni 2026	YoY
Omsætning	3,7 mia.	-
Bruttofortjeneste	499 mio.	-
Nettoresultat	302 mio.	-
EBITDA	797 mio.	-

Fundamentale data

Nøgletal	Værdi
Markedsværdi	15,39 mia. €
Antal aktier	173,6 mio.
Højeste/laveste i 52 uger	89,28 € - 54,86 €
Udbytteafkast	0,70 %
Udbytte TTM	0,61 €
Beta	0,81
P/E (PE Ratio)	29,55
PEG (PEG Ratio)	0,97
K/I (PB Ratio)	4,30
P/S (PS Ratio)	2,08

Virksomhedsprofil

Eurofins Scientific SE samt dets datterselskaber leverer forskellige analytiske testydelser og laboratorieydelser over hele verden. Virksomheden tilbyder en portefølje på cirka 200.000 analytiske metoder til at vurdere sikkerheden, identiteten, sammensætningen, autenticiteten, oprindelsen, sporbarheden og renheden af forskellige produkter. Den leverer ydelser som agro-videnskab, herunder biologisk vurdering, forbruger- og humanvidenskab samt miljøsikkerhed, produktkemi, regulatorisk rådgivning og frøydelser; agro-test; assurance, såsom produktinspektion, revision, certificering, uddannelse og rådgivning inden for fødevarer, forbrugerprodukter samt sundheds- og kosmetikprodukter; biopharma og klinisk diagnostik. Derudover tilbyder virksomheden forbrugerprodukttest, som omfatter produktoverensstemmelse og revision, test, certificeringer og godkendelser, inspektioner, kurser samt digitale medier og cybersikkerhed for forskellige brancher; kosmetik og personlig pleje; miljøtest, herunder test af vand, luft, jord, affald og andre produkter; og fødevare- og foderteste, som omfatter allergener, GMO, korn, kød, nanomaterialer, pesticider og test af restDNA. Endvidere tilbyder den revision og certificering, autenticitet, kulhydrater, rådgivning, dioxiner og POP'er, fødevarebestråling, mærkning, jura, tungmetaller, identitetsbevaring, måltider, molekylær- og mikrobiologi, mykotoksiner, ernæringsanalyser, økologiske kontaminanter, emballage/migration, radioaktivitet, rapidest, sensorik og forbrugerforskning, kurser, rester af veterinærlægemidler og vitaminydelser. Derudover leverer virksomheden ydelser inden for retsmedicin, genomik, maritime forhold, materialer og ingeniørarbejde, REACH og teknologi. Den driver cirka 900 laboratorier i 54 lande. Virksomheden blev grundlagt i 1987 og har hovedkontor i Luxembourg by, Luxembourg.